跳至主要内容
临床试验/CTRI/2025/09/094178
CTRI/2025/09/094178尚未招募不适用

To evaluate the in vivo dermatological safety and efficacy of a skin care formulation in terms of improvement in skin moisturisation, skin even tone and skin brightness, and reduction in dark spots i.e. Acne PIH on healthy female subjects.

Anivium technologies pvt. ltd1 个研究点 分布在 1 个国家目标入组 36 人开始时间: 2025年9月9日最近更新:

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
36
试验地点
1
主要终点
Improvement in skin moisturisation, skin even tone & skin brightness and reduction in dark spots (Acne PIH)

研究概览

简要总结

PRIMARY OBJECTIVE :The objective of this study will be to evaluate the in-vivo dermatological safety and efficacy of a skin care formulation in terms of  improvement in skin moisturisation, skin even tone & skin brightness and reduction in dark spots (Acne PIH) on healthy female subjects.

The evaluation is performed using:Subject Self Evaluation, Dermatological Evaluation: Cosmetic Acceptability, Chromametry , Corneometry, Mexametry, Digital Photographs

POPULATION : 36 female subjects will be selected for the study.

The subjects selected for this study are healthy males aged between 18 and 40 years, having normal skin type with visible Acne PIH spots, at least one acne spot of 3mm or more.

STUDY DURATION :  28 days following the first application of the product.

研究设计

研究类型
Interventional
分配方式
Na
盲法
Participant and Outcome Assessor Blinded

入排标准

年龄范围
18.00 Year(s) 至 40.00 Year(s)(—)
性别
Female

入选标准

  • 1.Indian female subjects 2.Healthy subjects 3.Skin is healthy on the studied anatomic unit 4.Having normal skin type with visible Acne PIH.spots, at least one acne spot of 3mm or more.

排除标准

  • Being pregnant or breastfeeding or having stopped to breastfeed in the past three months
  • Having refused to give her/his assent by not signing the consent form
  • Taking part in another study liable to interfere with this study
  • Being insulin-dependent diabetic or non-insulin-dependent diabetic with a recent therapy (less than 6 months)
  • Having a progressive asthma (either under treatment or last fit in the last 2 years)
  • Having a chronic dermatosis liable to modify the cutaneous reactivity on the tested area (except for specific studies on a determined dermatosis)
  • Having non stabilized thyroid problems (requirement of a stabilized treatment for at least 6 months)
  • Being epileptic.
  • Following a chronic medicinal treatment comprising any of the following products: aspirin-based products, anti-inflammatories, anti-histamines, corticotherapy, taken by general or local routes (the only medication permitted is paracetamol)
  • Having cutaneous hypersensitivity.
  • Having a diagnosed or highly probable allergy to one or several compounds of the cosmetic products.

结局指标

主要结局

Improvement in skin moisturisation, skin even tone & skin brightness and reduction in dark spots (Acne PIH)

时间窗: Baseline, 30 minutes, 14 days, 28 days

次要结局

未报告次要终点

研究者

发起方
Anivium technologies pvt. ltd
申办方类型
Other [Personal Care or Beauty Industry]
责任方
Principal Investigator
主要研究者

Dr Niharika Salian

MASCOT-SPINCONTROL India Pvt. Ltd.

研究点 (1)

Loading locations...

相似试验